After estimated the IC50 of 138 drugs in TCGA-STAD patients, we discovered that GC patients with high TMEM200A expression might gradually tolerate for AKT.inhibitor.VIII, Afatinib, Gefitinib, Lapatinib, and Metformin, while All-trans Retinoic Acid, Cytarabine, Nilotinib, and Crizotinib may have better therapeutic effects in these patients (Figure 9). The gene discussed is AKT1; the disease is gastric cancer.